

Emerging Companies and Investors - Life Sciences and Health Care

We don't just get you off the ground; we're here to grow with you.

We don't just get you off the ground; we're here to grow with you.

From corporate formation to patent protection and strategy to initial financing rounds, we help your company lay a strong foundation, with life sciences and health care industry expertise at the forefront throughout. As your business grows and your needs evolve, so does our team of lawyers who can support your company's strategic business needs relative to your product's development stage, including regulatory approval planning, clinical trial design, pricing and reimbursement strategy, licensing, collaborations and other commercial transactions, and commercialization and product launch planning.

[Read more about our capabilities](#)

Representative experience

Morphosys on a worldwide collaboration and license agreement with Incyte Corporation to co-commercialize tafasitamab for the treatment of B cell malignancies.

Contacts

Kristin Anne Connarn,
Boston

Beth L. Roberts,
Washington, D.C.

Andrew L. Strong,
Houston

Arne Thiermann, LL.M. (LSE),
Hamburg

Industries

Life Sciences and Health
Care

Pacira Pharmaceuticals on its agreement with DePuy Synthes to jointly market and promote the use of EXPAREL™ for orthopedic procedures in the U.S.

Kite Pharma, on its investment in HifiBio's US\$67m Series C financing.

Sensors for Medicine and Science on its US\$54.1m Series D financing.

Pyxis Oncology on IP strategy, patent prosecution, and supporting IP diligence for its \$168 million IPO and \$152 million Series B financing.

Genome Medical on patent prosecution, prior art searches, and patent strategy development.

Tessera Therapeutics on its IP needs including patent prosecution, strategy, and transactional matters.

Medical device start up in obtaining clearance of a 510(k) notice without clinical data for a cardiac bypass device after the FDA required PMA approval.

Heartflow in obtaining Medicare coverage and reimbursement for its new software technology.

Juno Therapeutics on its comprehensive FDA regulatory, reimbursement, and launch planning for its CAR-T therapies under development.

Leading digital health companies on data privacy matters with regard to clinical trials in the EU involving both pan-European strategic advice and detailed country-specific guidance.

Emerging biotech companies on data questions related to structuring clinical trials, informed consents, patient support programs, and specialty pharmacy arrangements.

Latest thinking and events

Webinar

Antitrust for emerging companies – what you need to know

Hogan Lovells Events

U.S. Market access strategy at the clinical stage for all companies considering a launch: A three-part series

Press Releases

Hogan Lovells advises OncoResponse on closing of \$50m senior secured loan

Sponsorships and Speaking Engagements

Beyond the Business Pitch at JP Morgan: Key Issues for Emerging Companies and Investors in 2022

Press Releases

Hogan Lovells advises Avidea Technologies on acquisition by Vaccitech